Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Unraveling KAdcyla (Trastuzumab Emtansine; T-DM1) Resistance In HER2-positive Advanced Breast Cancer (ABC): a Prospective GEICAM Study"

NCT03829306 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.

NCT NCT03829306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Unraveling KAdcyla (Trastuzumab Emtansine; T-DM1) Resistance In HER2-positive Advanced Breast Cancer (ABC): a Prospective GEICAM Study"
Lead sponsor
Spanish Breast Cancer Research Group
Phase
Observational
Overall status
Completed
Start date
June 12, 2018
Completion date
June 21, 2022
Enrollment
32 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer